论文部分内容阅读
新抗疟药甲氟喹(MEFL)在东南亚对具多种抗药性的恶性疟原虫引起的自然急性感染疗效甚佳。但近来在体外培育及患者体内均已发现抗MEFL恶性疟原虫。对伯氏疟原虫的研究表明,单用该药可导致原虫对MEFL产生抗性,但与乙胺嘧啶(PYR)和周效磺胺(SDX)伍用则可防止抗性的产生。本文报道了恶性疟原虫的体外研究结果。实验用的恶性疟原虫株系1982年分离自一马来亚患者,按Trager-Jensen氏蜡烛缸法建立连续培养。初期药效测定显示原虫对PYR及SDX均敏感。对MEFL的药敏性测定在培养后一月内进行。药测按烛缸小
The new antimalarial mefloquine (MEFL) works well in Southeast Asia for natural acute infections caused by multidrug resistant Plasmodium falciparum. However, anti-MEFL Plasmodium falciparum has recently been found in vitro and in patients. Studies with Plasmodium berghei showed that protozoa were resistant to MEFL only with this drug alone, but the combination with pyrimethamine (PYR) and sulfasalazine (SDX) prevented the development of resistance. This article reports the results of in vitro studies of Plasmodium falciparum. The experimental P. falciparum strain was isolated from a Malayian patient in 1982 and was serially cultured according to the Trager-Jensen candle jar method. The initial pharmacodynamics test showed that protozoa were sensitive to both PYR and SDX. Susceptibility to MEFL was measured within one month after culturing. Drug test by candle small